ITZYKSON , Raphael

Last name: ITZYKSON

First name: Raphael

December 13, 2012 (v1)

Journal article

Metadata-only

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience.

Lamarque, Mathilde Raynaud, Sophie Itzykson, Raphael

International audience

Uploaded on: December 2, 2022
February 21, 2024 (v1)

Publication

Metadata-only

Targeting Heterochromatin Eliminates Malignant Hematopoietic Stem and Progenitor Cells in Chronic Myelomonocytic Leukemia Through Reactivation of Retroelements and Innate Immune pathways

Hidaoui, Donia Chelbie, Rabie Bohm, Mathieu

Abstract Chronic myelomonocytic leukemia (CMML) is a severe myeloid malignancy affecting the elderly, for which therapeutic options are limited. DNA hypomethylating agents (HMAs) provide transient responses, failing to eradicate the malignant clone. Hematopoietic stem cell (HSC) aging involves a reorganization of heterochromatin, evidenced by...

Uploaded on: February 23, 2024
2018 (v1)

Journal article

Metadata-only

Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial

Itzykson, Raphael Fournier, Elise Braun, Thorsten

60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, DEC 01-04, 2018

Uploaded on: December 3, 2022
2021 (v1)

Journal article

Metadata-only

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

Itzykson, Raphael Fournier, Elise Berthon, Celine

To design a simple and reproducible classifier predicting the overall survival (OS) of patients with acute myeloid leukemia (AML) >= 60 years of age treated with 7+3, we sequenced 37 genes in 471patients fromtheALFA1200 (Acute Leukemia FrenchAssociation) study (median age, 68 years). Mutation patterns and OS differed between the 84 patients...

Uploaded on: December 3, 2022

ITZYKSON , Raphael

Recent uploads